Two Depression Medicines Helped People With Epilepsy Equally

What was studied

This study evaluated two antidepressants, agomelatine and escitalopram, in people with epilepsy who also had major depressive disorder. It was a double-blind, randomized, phase IV study, meaning participants were assigned by chance to one of the two medicines, and neither the participants nor the researchers knew which medicine each person was taking during the study.

The study took place at three centers. Sixty-four people were screened, and 51 were randomized to agomelatine 25 mg or escitalopram 10 mg. The researchers measured depression, seizure frequency, sleep, daytime sleepiness, quality of life, and cognitive performance including memory.

What they found

Both medicines were associated with improvement in depression scores over time, and there was no significant difference between the groups for depression. The study also found no significant between-group differences in seizure frequency, sleep quality, or daytime sleepiness, and no significant changes in seizure frequency, PSQI, or ESS scores were observed in either group.

Quality of life improved significantly only in the escitalopram group. Verbal memory improved significantly only in the agomelatine group after correction for multiple comparisons. Cognitive changes observed with escitalopram did not remain significant after correction. Adverse events were mild to moderate (7.8%), and no serious adverse event occurred.

Limits of the evidence

This was a small study, with only 51 people randomized, so it may have missed smaller differences between the medicines. The abstract does not report how long treatment lasted, which limits interpretation of longer-term benefits and risks.

The study compared two active medicines but did not include a placebo group, so it cannot determine how much of the improvement was related to the medicines versus other factors. Larger studies are needed to confirm these findings.

For families and caregivers

For families, this study suggests that treatment of depression in people with epilepsy was associated with improved depressive symptoms in this small trial, without worsening seizure frequency, sleep, or daytime alertness.

The results also suggest the two medicines may have somewhat different patterns of benefit: escitalopram showed a more consistent pattern for mood and quality of life, while agomelatine was associated with improved verbal memory after correction for multiple testing. Because the study was small, these findings need confirmation in larger studies.

What to watch next

Larger studies that follow people longer would help confirm these findings and clarify effects on mood, quality of life, cognition, seizure frequency, and side effects over time.

Terms in this summary

major depressive disorder

A medical condition that causes ongoing low mood and other symptoms, such as loss of interest, sleep problems, or trouble concentrating.

double-blind

A study design in which neither the participants nor the researchers know who is getting which treatment during the study.

randomized controlled trial

A study where people are assigned by chance to different treatments so the groups can be compared fairly.

quality of life

A person's overall well-being in daily life, including physical, emotional, and social health.

verbal memory

The ability to remember words and spoken information.

multiple comparisons

When researchers do many statistical tests, they adjust the results to lower the chance of finding a false positive by luck alone.